Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ofatumumab approved dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ofatumumab dose 1 | ACTIVE_COMPARATOR | Approved dosage |
| Ofatumumab dose 2 | EXPERIMENTAL | New dosage |
| Name | Type | Description |
|---|---|---|
| Ofatumumab approved dose | BIOLOGICAL | Approved dosage |
| Ofatumumab new dose | BIOLOGICAL | New dosage |
Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study. * Male or female study participants aged 18 to 60 years (inclusive) at screening. * Diagnosis of multiple sclerosis (MS) according to the 2017 Revised McDonald criteria (Thompson et al 2018). Relapsi...
Ofatumumab approved dose is a monoclonal antibody being developed for relapsing multiple sclerosis (RMS). It is currently in Phase 3 clinical development and is being studied in a trial that includes patients with RMS. The drug is administered as a maintenance dosing regimen.
Ofatumumab approved dose is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting a Phase 3 clinical trial to evaluate the drug in patients with relapsing multiple sclerosis.
Ofatumumab approved dose is in Phase 3 clinical development. It is being studied in an active-controlled trial for relapsing multiple sclerosis, with the trial currently active but not recruiting participants.
Ofatumumab approved dose is being evaluated in a Phase 3 trial with the identifier NCT06869785. This trial is studying the pharmacokinetics, pharmacodynamics, safety, and tolerability of a new maintenance dosing regimen of ofatumumab in patients with relapsing multiple sclerosis.
Ofatumumab approved dose is a monoclonal antibody, which is a type of -mab antibody. As an antibody-based therapy, it is designed to interact with specific targets in the immune system, though the specific molecular target is not detailed here.
Ofatumumab approved dose is a specific formulation or dosing regimen of ofatumumab, which is being studied for relapsing multiple sclerosis. The name indicates it is an approved dose of ofatumumab, but the drug is still in clinical development for this indication.